Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534944 · ClinicalTrials.gov registry record · Phase 1
NAD Supplementation and Vascular Health in PAD
A Phase 1 study of Peripheral Artery Disease, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06534944: Completed Phase 1 study of Peripheral Artery Disease, sponsored by University of Oklahoma.
NCT06534944 is a Phase 1 study of Peripheral Artery Disease that has completed, run by University of Oklahoma. The registered enrollment target is 8 participants, below the 127-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06534944, a Phase 1 study of Peripheral Artery Disease, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.
Primary Outcome
Functional near infrared spectroscopy (fNIRS) will be performed during the cognitive n-back task. fNIRS approach generates data that represent a relative change in oxygenated and deoxygenated hemoglobin measured over the cortical brain tissues. Neurovascular coupling will be evaluated as a change in oxy- and deoxy-hemoglobin between before and after treatment. Units of measure - beta. Reported as a change from baseline, before and after treatment.
Conditions Studied
Interventions
- DRUG Nicotinamide riboside
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the finished NCT06534944 record still lists
NCT06534944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 127-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide riboside is the first listed.
NCT06534944 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06534944 about?
NCT06534944 is a clinical study titled "NAD Supplementation and Vascular Health in PAD". This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.
What is the current status of trial NCT06534944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-02-27. Estimated completion is 2024-12-30.
What conditions does trial NCT06534944 study?
This clinical trial studies the following conditions: Peripheral Artery Disease.
What interventions are being tested in trial NCT06534944?
The interventions under investigation include: Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT06534944?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534944 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06534944's enrollment target sits among peer trials
8 50th of 50 higher than 1 of 50 other Peripheral Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
RECRUITING · Phase 1
-
Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
COMPLETED · Phase 1
-
Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)
COMPLETED · Phase 1
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI